Claritev Corp (CTEV): Results of Operations and Financial Condition
Claritev Corp (CTEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. E Claritev Corporation Reports Second Quarter 2026 Results – Q2 2026 Revenues of $257.5 million grew 6.6% compared to Q2 2025 – Net Loss of $59.2 million – Adjusted EBITDA of $155.8 million increased 1.1% compared to Q2 2025 (Adjusted EBITDA Margin of 60.5% versus 63.8% in Q2 202
How this was made
The 30-second read
Why it matters
Traders can update models around the updated revenue, Adjusted EBITDA, and free cash flow ranges, and reassess near-term expectations ahead of the scheduled earnings call.
Market read
Q2 results show YoY revenue growth and improved operating cash flow and free cash flow, alongside updated FY 2026 guidance ranges.
What to watch
Unrestricted cash is only $14.4M at quarter end, and free cash flow guidance remains relatively tight ($5M-$15M), so liquidity and conversion risk may matter more than headline revenue growth.
Background
This is an SEC Form 8-K (Item 2.02) with an attached earnings press release covering Q2 2026 results and updated FY 2026 guidance.
Ticker impact
Claritev reported Q2 2026 results and updated full-year 2026 guidance, including revenue $1.00B-$1.02B and Adjusted EBITDA $610M-$620M.
Moderate upside bias if investors view the updated revenue and EBITDA range as credible and FCF trajectory improving.
Q2 shows year-over-year revenue growth and higher operating cash flow and free cash flow, and management raised/updated full-year ranges; however, the release does not include consensus comparisons or a clear surprise magnitude.
Market effects
Healthcare data and insights peers may see read-through on demand strength and AI-driven execution narratives, but impact is likely company-specific.
Limited, as the disclosure is issuer-specific with no broader regional macro signal.
Low, since the guidance and results are not tied to global regulatory or cross-border events.
Counterpoint
Despite revenue growth, the company still reported a large net loss, and Adjusted EBITDA margin declined versus Q2 2025, which could temper enthusiasm.
Key entities
- issuerClaritev Corporation
Technology, data, and insights company focused on healthcare affordability, transparency, and fairness.
- executiveTravis Dalton
Chairman, CEO, and President, quoted on strategy execution and bookings strength.
- executiveDoug Garis
CFO, quoted on revenue and Adjusted EBITDA performance and client success focus.
